JP2018534288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534288A5 JP2018534288A5 JP2018519487A JP2018519487A JP2018534288A5 JP 2018534288 A5 JP2018534288 A5 JP 2018534288A5 JP 2018519487 A JP2018519487 A JP 2018519487A JP 2018519487 A JP2018519487 A JP 2018519487A JP 2018534288 A5 JP2018534288 A5 JP 2018534288A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- cytarabine
- aml
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087311A JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242256P | 2015-10-15 | 2015-10-15 | |
| US62/242,256 | 2015-10-15 | ||
| US201562255194P | 2015-11-13 | 2015-11-13 | |
| US62/255,194 | 2015-11-13 | ||
| PCT/US2016/057083 WO2017066599A1 (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087311A Division JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534288A JP2018534288A (ja) | 2018-11-22 |
| JP2018534288A5 true JP2018534288A5 (https=) | 2019-11-28 |
Family
ID=57208385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519487A Withdrawn JP2018534288A (ja) | 2015-10-15 | 2016-10-14 | 悪性腫瘍の治療のための併用療法 |
| JP2021087311A Pending JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087311A Pending JP2021130682A (ja) | 2015-10-15 | 2021-05-25 | 悪性腫瘍の治療のための併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10905692B2 (https=) |
| EP (2) | EP3362057A1 (https=) |
| JP (2) | JP2018534288A (https=) |
| KR (2) | KR20250065944A (https=) |
| CN (1) | CN108366980A (https=) |
| AU (1) | AU2016340087C1 (https=) |
| BR (1) | BR112018007304A2 (https=) |
| CA (1) | CA3001599A1 (https=) |
| CL (1) | CL2018000927A1 (https=) |
| EA (1) | EA201890968A1 (https=) |
| IL (2) | IL311873A (https=) |
| MX (2) | MX394796B (https=) |
| SG (1) | SG10201912886XA (https=) |
| WO (1) | WO2017066599A1 (https=) |
| ZA (1) | ZA201802088B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| US10980788B2 (en) * | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| WO2011050211A2 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
-
2016
- 2016-10-14 CN CN201680060067.1A patent/CN108366980A/zh active Pending
- 2016-10-14 SG SG10201912886XA patent/SG10201912886XA/en unknown
- 2016-10-14 KR KR1020257014978A patent/KR20250065944A/ko active Pending
- 2016-10-14 KR KR1020187010260A patent/KR20180063125A/ko not_active Ceased
- 2016-10-14 AU AU2016340087A patent/AU2016340087C1/en active Active
- 2016-10-14 IL IL311873A patent/IL311873A/en unknown
- 2016-10-14 EP EP16787982.4A patent/EP3362057A1/en not_active Withdrawn
- 2016-10-14 CA CA3001599A patent/CA3001599A1/en not_active Abandoned
- 2016-10-14 WO PCT/US2016/057083 patent/WO2017066599A1/en not_active Ceased
- 2016-10-14 MX MX2018004595A patent/MX394796B/es unknown
- 2016-10-14 US US15/768,480 patent/US10905692B2/en active Active
- 2016-10-14 EP EP22196348.1A patent/EP4147692A1/en active Pending
- 2016-10-14 EA EA201890968A patent/EA201890968A1/ru unknown
- 2016-10-14 BR BR112018007304A patent/BR112018007304A2/pt not_active Application Discontinuation
- 2016-10-14 JP JP2018519487A patent/JP2018534288A/ja not_active Withdrawn
-
2018
- 2018-03-21 IL IL258269A patent/IL258269A/en unknown
- 2018-03-28 ZA ZA2018/02088A patent/ZA201802088B/en unknown
- 2018-04-11 CL CL2018000927A patent/CL2018000927A1/es unknown
- 2018-04-13 MX MX2022006701A patent/MX2022006701A/es unknown
-
2020
- 2020-12-24 US US17/133,994 patent/US20210386749A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087311A patent/JP2021130682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534288A5 (https=) | ||
| JP2018535951A5 (https=) | ||
| JP2018534286A5 (https=) | ||
| JP2019513694A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| JP2024133474A5 (https=) | ||
| JP2016517851A5 (https=) | ||
| JP2019505529A5 (https=) | ||
| JP2021523159A5 (https=) | ||
| JP2018536636A5 (https=) | ||
| JP2014513110A5 (https=) | ||
| JP2018517686A5 (https=) | ||
| FI3362065T3 (fi) | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi | |
| JP2020507589A5 (https=) | ||
| JP2015508749A5 (https=) | ||
| JP2010515715A5 (https=) | ||
| JP2012525393A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| IL311873A (en) | Combination therapy for treating malignancies | |
| JP2021534129A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| JP2019535723A5 (https=) | ||
| JP2016510326A5 (https=) | ||
| JP2015512432A5 (https=) | ||
| JP2019501879A5 (https=) |